Navigation Links
Drug TEMODAL and Radiotherapy for brain cancer treatment

Canada Health Government has approved the drug TEMODAL in combination with Radiotherapy for treating patients with glioblastoma multiforme brain cancer. // The drug TEMODAL that contains Temozolomide is produced by Schering-Plough Corporation and is used in treating two forms of brain cancer Glioblastoma multiforme and anaplastic astrocytoma.

Clinical study using the drug TEMODAL was tested on newly diagnosed glioblastoma multiforme patients by researchers from National Cancer Institute, Canada and European organization for Research and Treatment of Cancer and they found the drug to be effective in controlling the growth of malignant cells in the brain, by producing cytotoxic effect on cancer cells and prevents replication and production of cancer cells. Researchers have found on a clinical study on 573 patients that a combination of drug TEMODAL and radiotherapy in brain cancer patients reduces the tumor burden and significantly increases the survival of the cancer patients. The drug has been shown very effective but is found to cause mild side effects of myelosuppression in patients and the researchers have reported the results of their study in the Journal the New England Journal of Medicine.


'"/>




Page: 1

Related medicine news :

1. Radiotherapy helps in colon cancer
2. Link between Obesity and Post-Radiotherapy Outcome in Prostate Cancer Patients
3. Booster Dose Of Radiotherapy Beneficial In Early Breast Cancer
4. Patients Receiving Treatment with Radiotherapy Might trigger Security Alarms
5. Recurrence of bowel cancer cut down by Radiotherapy
6. Radiotherapy Centers in Scotland Undergo Inspection
7. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
8. Two doctors suspended for wrong brain surgery
9. The brain loves a surprise
10. Increase in sugar...decrease in brain function!!!
11. Alcohol shrinks brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: